Rise and shine, everyone, the middle of the week is here. You made it this far, so why not forge ahead, yes? As always, we are doing our best with the help of some cups of stimulation — we are quaffing hazelnut this morning — and invite you to join us. After all, a prescription is not required, so go ahead and indulge. Meanwhile, we have assembled the latest menu of tidbits to get you started on another busy day. Hope all goes well and you conquer the world. Cheers …
Mylan (MYL) priced its generic version of Advair, the blockbuster GlaxoSmithKline (GSK) asthma treatment, 70 percent lower than the branded medicine, Reuters notes. The medication, which is the first generic version of Advair, is approved in three doses and will be priced between $93.71 and $153.14. Advair targets certain patients with asthma or chronic obstructive pulmonary disease and brought in revenue of about $4.19 billion in 2017 for Glaxo. Mylan received approval for the treatment from the Food and Drug Administration last month.
About the Author Reprints
